Liver Cancer Clinical Trials

Clinical trials are research studies that involve people. The clinical trials on this list are for liver cancer. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 201-221 of 221
< Previous 1 ... 7 8 9

  • Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Participants With Advanced PD-L1 Positive Malignancies

    The primary objective of the study is to determine the safety and tolerability of 89Zr-DFO-REGN3504. The secondary objectives of the study are: Study Part A only: - To establish adequate mass dose and activity dose of 89Zr˗DFO˗REGN3504 and optimal post-infusion imaging time, as assessed by imaging and blood draw after tracer infusion Study Part B only: - To establish test / re-test reliability of positron emission tomography (PET) measures as assessed on 2 separate tracer infusions at adequate mass dose and optimal imaging time point as determined in Part A - To characterize the pharmacokinetic (PK) profile of 89Zr˗DFO˗REGN3504 based on tracer plasma activity concentration
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • Biomarker Testing in Studying APAP-CYS Concentrations in Primary or Secondary Liver Cancer Patients with Non-acetaminophen Induced Liver Injury

    This phase IV trial studies APAP-CYS concentrations in primary or secondary liver cancer patients with non-acetaminophen induced liver injury after taking therapeutic doses of acetaminophen. This research may help doctors in the future better understand protein adduct concentrations in patient’s blood.
    Location: University of Colorado Hospital, Aurora, Colorado

  • Symptom Management Implementation of Patient Reported Outcomes in Oncology

    Deficits in the management of common symptoms cause substantial morbidity for cancer patients.Because the health care delivery system is structured to be reactive and not proactive, there are missed opportunities to optimize symptom control. Growth in Internet access and proliferation of smartphones has created an opportunity to re-engineer cancer care delivery. Electronic symptom tracking and feedback is a promising strategy to improve symptom control. Electronic patient reported outcome (ePRO) monitoring of cancer symptoms has been shown to decrease symptom burden, improve quality of life, reduce acute care and even extend survival. SIMPRO will use functioning ePRO prototypes to create and refine the electronic symptom management system eSyM
    Location: 3 locations

  • Patient Portal and Navigation Program in Providing Information for Asian American Cancer Patients

    This trial studies how well patient portal and navigation program work in providing information for Asian American cancer patients. Patient portal and navigation program may help to improve the care provided to Asian American cancer patients.
    Location: 2 locations

  • Liver Cancer Community Education

    This trial studies how best to educate communities about liver cancer. Educating communities may combat rising liver cancer rates attributed to hepatitis B and C infection in Philadelphia by identifying neighborhoods with higher than expected rates of liver cancer and related risk factors.
    Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania

  • 360-Degree HoloLens Display in Providing Guidance during Percutaneous Ablation Procedure in Patients with Solid Liver Tumors

    This trial studies how well a 360-degree holographic display (using the HoloLens headset) works in providing guidance for percutaneous ablation in patients with solid liver tumors. Medical images of cancer are used to guide treatment of tumors. The HoloLens headset and display allows tumors to be viewed in true 3-dimensional (D) images ("360 degrees") during procedures in the operating room. The additional 3D visualization may facilitate complete ablation of solid tumors in the liver or other organs as compared to the standard flat screen display.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • MRI in Predicting Liver Toxicity in Patients with Liver or Intrahepatic Bile Duct Cancer Undergoing Radiation Therapy

    This pilot clinical trial studies magnetic resonance imaging (MRI) in predicting liver toxicity in patients with liver or intrahepatic bile duct cancer undergoing radiation therapy (RT). MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. Imaging procedures, such as MRI, may help doctors predict which patients will develop liver toxicity and help plan the best treatment.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma

    Clinical guidelines (AASLD) recommend the use of abdominal ultrasound (US) for surveillance testing for the early detection of Hepatocellular Carcinoma (HCC). The serum protein biomarker alpha-fetoprotein (AFP) is commonly used to augment US but its use alone is not recommended by clinical guidelines. Despite evidence that HCC surveillance improves early detection and reduces mortality from HCC, current HCC surveillance tests lack sensitivity, leaving a significant proportion of patients to present with late-stage disease. The Glycotest HCC Panel has shown better sensitivity than AFP, which is ineffective for the detection of early-stage HCC. This clinical study seeks to validate the Glycotest HCC Panel using a large multicenter cohort of cases and controls that includes patients diagnosed with early-stage HCC against a background of cirrhosis and cirrhotic patients without HCC (at risk) undergoing an established surveillance protocol.
    Location: 5 locations

  • Patient-Derived Xenografts to Reduce Cancer Health Disparities

    This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial / ethnic minorities. Understanding the genetic and response differences among racial / ethnic minorities may help researchers enhance the precision of therapeutic treatments.
    Location: 4 locations

  • Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

    The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.
    Location: 6 locations

  • Characterization of Mechanical Tissue Properties in Patients with Pancreatic, Liver, or Colon Cancer

    This pilot research trial studies characterization of mechanical tissue properties in patients with pancreatic, liver, or colon cancer. Mechanical properties and stiffness of the cancerous tissue may be correlated with the standard pathology report that describes the stage of the disease.
    Location: 3 locations

  • Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

    Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study. The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.
    Location: 2 locations

  • Clinical Trial for the IvyGene Liver Cancer Test

    This is a clinical trial designed to evaluate the performance of the IvyGene Dx Liver Cancer Test alone, ultrasound alone and the combination of both the IvyGene Dx Liver Cancer Test and ultrasound for the detection of HCC within a population that is at high risk for HCC due to liver cirrhosis.
    Location: 2 locations

  • NOLA (NeuWave Observational Liver Ablation) Registry

    This is a multicenter, observational registry that follows patients for a total of 5 years from the date of the first liver ablation procedure with the NEUWAVE Microwave Ablation System.
    Location: 2 locations

  • Prospective Cohort Study on the Clinical Trajectory of Resected Hepatocellular Carcinoma

    Hepatocellular carcinoma (HCC) is the 6th most common cancer in the world but the 2nd most important cause of cancer death. Because of its highly heterogeneous nature, the current approach to identifying druggable targets have not delivered efficacious therapies in HCC and is a main reason for the high case fatality. Even when surgical resection is potentially curative in early disease, tumor recurrence remains high and long term survival poor because of the absence of useful adjuvant therapy. To address these unmet needs, the investigators bring together internationally recognized scientists from genomics and immunology and established clinician investigators in a synergistic team. This TCR capitalizes on recent collaborative advances made by the PIs in the consortium. The investigators have shown through multi-region sampling of freshly resected HCC and phylogenetic analysis, that significant intra-tumoral heterogeneity exists and have identified the specific positions of known clonal drivers. Simultaneously the investigators have analyzed the immune landscape of the tumor microenvironment with deep immune-phenotyping and found unique inter-patient immune landscapes predictive of clinical trajectory. This TCR is a prospective study that samples resected HCC from multi-ethnic sites within the established Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group, which has enrolled approximately 1000 patients through 6 multi-center trials in 35 centers in the region. Clinical trajectories are tracked and genomic and immunological studies are repeated when tumors recu r, to confirm clonally dominant driver mutations and immunological processes that are targetable. Concurrently, representative pre-clinical models will be developed from the tissues sampled. The investigators aim to combine these approaches to overcome the challenges posed by genomic heterogeneity and to guide the development of therapeutics and precision medicine in HCC.
    Location: Duke University Medical Center, Durham, North Carolina

  • Magnetic Resonance Imaging in Planning Radiation Therapy in Patients with Liver, Brain, Head and Neck, or Pelvic Cancer

    This pilot clinical trial studies magnetic resonance imaging in planning radiation therapy in patients with liver, brain, head and neck, or pelvic cancer. Magnetic resonance imaging may help in planning radiation therapy and may result in more tumor cells being killed.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

    This study aims to provide long-term follow-up care of patients previously enrolled in a vaccine study that involved poxviral vectors. Vectors are sequences of genetic material that can be used to introduce specific genes into genetic makeup. The study does not involve the use of any drug or biologic agent. Participants will undergo an annual health history. Because certain viruses enter into cells and create proteins from the viral genes, the type of vaccine treatment used is referred to gene therapy. The genes expressed by poxviral vectors do not become part of the genetic material left behind. Because gene therapy is a somewhat new technology, a prolonged monitoring of patients' health status is necessary, according to new specific reporting requirements for harmful events in patients who undergo such gene therapy studies. The risk of any long-term negative effects from the gene therapy that patients had received is quite small. Still, it is important that there be updates at least annually. This annual monitoring of health status will extend for 15 years, according to guidelines from the Food and Drug Administration, or for as long as patients are willing to participate. Patients who received poxviral vectors (vaccinia or fowlpox, or both) at the National Cancer Institute, through a trial affiliated with the Laboratory of Tumor Immunology and Biology, may be eligible for this study. Participants will be involved in the following forms of data collection: - Annual medical history and physical examinations for the first 5 years following the last vaccine. - Annual telephone contact during the last 10 years. - Health status check, including primary cancer status, secondary malignancies, neurologic disorders, autoimmune disorders, and hematologic disorders. - Blood tests for the presence of HIV antibodies. - Reporting of medical problems, including information on unexpected hospitalizations and medications. If a participant has died, the study will document the cause of death and autopsy information if available. ...
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Registry Study of Neoadjuvant Therapy in Conjunction with Liver Transplantation for Cholangiocarcinoma

    This study collects information about treatments received on patients with unresectable cholangiocarcinoma, a cancer of the bile duct inside the liver that cannot be removed without a liver transplant. Collecting information on patients about tests or procedures that they have had or will have, may help researchers estimate the rates of response to treatment and withdrawal from treatment.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Collection of Blood From Patients With Cancer

    This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment. Participants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Circulating Tumor DNA Exposure in Peripheral Blood

    This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the detection of circulating tumor DNA (ctDNA).
    Location: Banner University Medical Center - Tucson, Tucson, Arizona

  • National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer

    Background: Primary Liver Cancer is the second most common cause of cancer-related death worldwide. It is the cancer with the fastest rising incidence and mortality in the United States. Researchers want to learn more about liver cancer to help them design better treatments. Objective: To better understand liver cancer. Eligibility: People ages 18 and older who have liver cancer and had or are planning to have immune therapy Design: Participants will be screened with a review of their medical records. They will be asked about their medical history and test results. Participants will come to the NIH Clinical Center. During this visit, their medical records, test results, imaging studies, and tissue samples (if available) will be gathered. Participants will learn the results of a test to see if they have any mutations known to be connected to cancer. They will learn if there are treatment options for them. Participants will give blood, urine, and stool samples or rectal swabs. Participants will not have follow-up visits just for this study. If they join another NIH research study and have visits for this other study, their medical records; test results; and blood, urine, and stool samples may be collected. This will occur about every 3 months. If they have a biopsy or surgery on another study or as part of treatment and there is leftover tissue, researchers would like to collect some of that tissue. Participants will be contacted every 6 months by phone or e-mail. They will be asked about their health. They will provide any medical records, test results, and imaging studies. Participants will be followed on this study for life.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

< Previous 1 ... 7 8 9